Core Viewpoint - The article highlights a case of commercial bribery involving Shanghai Haiyilai Consulting Management Partnership, which engaged in unethical practices to promote a specific drug, leading to administrative penalties and potential impacts on the involved companies' reputations and operations [2][3][4][5] Group 1: Company Actions and Penalties - Shanghai Haiyilai Consulting Management Partnership was found to have paid improper benefits to a clinical doctor to influence prescription behavior for the drug "Dahansuan Sodium Injection" [2] - The company received a total service income of 868,677 yuan from Shanghai Hongjian Pharmaceutical Co., and was fined 300,000 yuan by the Shanghai Putuo District Market Supervision Administration for commercial bribery [3] - The sales promotion director of Haiyilai promised the doctor a "benefit fee" for increased prescriptions, resulting in a total transfer of 35,046 yuan over four transactions [2][3] Group 2: Implications for Related Companies - The case has implications for Hebei Changshan Biochemical Pharmaceutical Co., which is linked to the drug involved and is a publicly listed company in China [3] - The annual sales of "Dahansuan Sodium Injection" exceed 170 million yuan, with a reported 26.68% year-on-year increase in sales volume, although revenue remained stable due to price declines [3] - The National Healthcare Security Administration has established a credit evaluation system since 2020 to assess pharmaceutical companies involved in commercial bribery, which may affect Changshan Pharmaceutical's credit rating in drug procurement [4][5]

Core Insights - The case involves commercial bribery linked to the pharmaceutical industry, specifically between Haiyilai Company and Hongjian Pharmaceutical Company regarding the promotion of a drug called Danheparin Sodium Injection [1][2][4] Group 1: Company Actions - Haiyilai Company signed a one-year information service agreement with Hongjian Pharmaceutical Company to promote Danheparin Sodium Injection in Shanghai [1] - During the period from January to December 2023, Haiyilai's sales promotion director made four personal WeChat transfers totaling 35,046 yuan to a doctor to incentivize the prescription of the drug [2] - The total revenue generated by Haiyilai from the marketing and information services for Danheparin Sodium in 2023 was 868,677 yuan [2] Group 2: Regulatory Response - The Shanghai Putuo District Market Supervision Administration imposed a fine of 300,000 yuan on Haiyilai Company for commercial bribery [2] - The National Medical Insurance Administration emphasized that such bribery undermines fair competition and increases the burden on the healthcare system [4] - The case has prompted a credit evaluation process for the involved companies, including Hongjian Pharmaceutical and its supplier, Hebei Changshan Biochemical Pharmaceutical Company [2][4] Group 3: Industry Context - Hebei Changshan Biochemical Pharmaceutical Company, also known as Changshan Pharmaceutical, is a publicly listed company specializing in cardiovascular drugs and has a complete heparin product supply chain [3] - Danheparin Sodium Injection, a key product for Changshan Pharmaceutical, generated over 170 million yuan in sales annually and is used for treating various cardiovascular conditions [3] - The company plans to increase the promotion of Danheparin Sodium Injection, with a projected sales volume growth of 26.68% in 2024, although revenue is expected to remain stable due to price declines [3]

Core Viewpoint - The National Medical Insurance Administration has announced a commercial bribery case involving a doctor from a women's and children's hospital in Shanghai, who received a benefit fee of 35,000 yuan for prescribing a drug, leading to a fine of 300,000 yuan for the involved company, Shanghai Haiyilai Enterprise Consulting Management Partnership [1][2] Group 1 - The involved company, Haiyilai, signed a one-year information service agreement with Hongjian Pharmaceutical Co., Ltd. to promote the drug "Dahansuan Sodium Injection" (brand name: Wanmai Ning) in Shanghai [1] - Haiyilai promised to maintain and increase the total sales of Wanmai Ning in Shanghai in exchange for the marketing service contract [1] - The sales promotion director and shareholder of Haiyilai promised the doctor a benefit fee for prescribing the drug, resulting in a total of 18,275 units prescribed during the year [1] Group 2 - The total income from market promotion and information services for Wanmai Ning in 2023 was 868,677 yuan [1] - The market supervision authority determined that Haiyilai's actions constituted commercial bribery, violating the Anti-Unfair Competition Law of the People's Republic of China [2] - An administrative penalty of 300,000 yuan was imposed on Haiyilai for its actions [2]

Core Viewpoint - The article discusses a case of commercial bribery involving a pharmaceutical consulting firm and its efforts to promote a specific drug in Shanghai, highlighting the implications for fair competition and healthcare costs in the industry [1][4]. Group 1: Case Details - In January 2023, the consulting firm signed a one-year information service agreement with Hongjian Pharmaceutical Company to promote the drug "Dahansuan Sodium Injection" in Shanghai [2]. - The consulting firm promised to increase the sales volume of the drug and engaged in bribery by offering benefits to doctors in exchange for prescriptions, totaling 35,046 yuan over four transactions [2][3]. - The firm earned a total of 868,677 yuan from the marketing and information services related to the drug during the year [2]. Group 2: Regulatory Actions - The Shanghai Putuo District Market Supervision Administration issued an administrative penalty of 300,000 yuan to the consulting firm for violating the Anti-Unfair Competition Law by using bribery to gain competitive advantages [3]. - The National Healthcare Security Administration has established a credit evaluation system to penalize companies involved in bribery and unfair competition, aiming to protect patient rights and ensure fair market practices [4]. Group 3: Industry Implications - The article emphasizes that pharmaceutical commercial bribery distorts prescription practices and increases healthcare costs, shifting the focus from clinical value to improper competition driven by high rebates [4]. - The ongoing issues of inflated drug prices and the need for regulatory oversight are highlighted, as they continue to affect both patients and compliant companies in the industry [4].

Core Viewpoint - The article discusses the investigation and administrative penalties imposed on Shanghai Haiyilai Enterprise Consulting Management Partnership for engaging in commercial bribery related to the marketing of a pharmaceutical product, specifically "Dahansuan Sodium Injection" [1][3]. Group 1: Investigation Details - In April 2025, the Shanghai Putuo District Market Supervision Administration discovered that the company was involved in commercial bribery during its market service activities in Shanghai [1]. - The company signed a one-year information service agreement with Shanghai Hongjian Pharmaceutical Co., Ltd. in January 2023 to promote the sales of "Dahansuan Sodium Injection" [2]. - The company promised to maintain and increase the total sales of the product in Shanghai and offered benefits to doctors to encourage them to prescribe the drug [2]. Group 2: Financial Transactions - Between January and December 2023, the sales promotion director made four payments totaling 35,046 yuan as bribes to a doctor in exchange for prescriptions of the drug, resulting in 18,275 units being prescribed [2]. - The total revenue from market promotion and information services for the product in 2023 amounted to 868,677 yuan [2]. Group 3: Legal and Regulatory Implications - The investigation was supported by various documents, including inquiry records, service agreements, and payment records, leading to the conclusion that the company violated the Anti-Unfair Competition Law of the People's Republic of China [3]. - The company was fined 300,000 yuan for its actions, which were deemed as commercial bribery aimed at increasing product sales [3]. Group 4: Industry Impact - The article highlights that pharmaceutical commercial bribery undermines fair competition and increases the burden on healthcare, shifting sales from clinical value to improper competition driven by high rebates [4]. - The National Healthcare Security Administration has implemented a credit evaluation system to address issues of bribery and misconduct in pharmaceutical sales, aiming to ensure fair competition and protect the rights of patients and compliant businesses [4].